Merus kündigt Poster-Präsentation über klinische Daten zu MCLA-145 beim ESMO Immuno-Oncology Congress 2021 an

NEXT STORY
HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China
PREV STORY
Talis Biomedical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Antimicrobial Resistance Diagnostic Markets, Strategies and Trends Report 2021-2025: Will Diagnostics Solve the Problem – Multiple Diagnostic Technologies Create New Global Race

author_avatar
NASDAQ Market News

Innovation Pharmaceuticals Reports p53 Drug Candidate Therapeutic Potential Further Supported by Academic Research in Leukemias and in Combination with Cancer Immunotherapies

author_avatar
NASDAQ Market News

Motus GI Announces Publication of Pure-Vu® System Clinical Data in Peer-Reviewed Journal BMC Gastroenterology

author_avatar
NASDAQ Market News